Sucralfate (sucralfate oral) NDC 52817-840

NDC codes

FDA NDC Directory

Product NDC (as listed)52817-840Labeler and product segments. Claims need a package NDC.

Product NDC at billing width52817-0840Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
52817-840-16	52817084016	473 mL in 1 BOTTLE (52817-840-16)Marketed from Apr 1, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate
Generic name (nonproprietary): sucralfate oral
Active ingredients: Sucralfate — 1 g/10mL
Dosage form: Suspension
Route: Oral
Labeler: TruPharma, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213549
Marketing start: Apr 1, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 52817-840_4718799e-e742-c93e-e063-6294a90aacfdSPL ID 4718799e-e742-c93e-e063-6294a90aacfdSPL set ID 7d441128-45d2-4bf2-817b-665784992e90RxCUI 313123UNII XX73205DH5UPC 0352817840165
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N452817084016 followed by a unit qualifier and the quantity

Package 52817-0840-16. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 29, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate Oral Suspension is Sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)